Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009361:Neoplasm Invasiveness / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010793:Phthalazines / Q000627:therapeutic use; D011379:Prognosis; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D018570:Risk Assessment; D000077210:Sunitinib; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D007211:Indoles; D010793:Phthalazines; D011725:Pyridines; D011758:Pyrroles; C404768:vatalanib; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D000077210:Sunitinib